Resources from the same session
1358O - Clinical qualification of transcriptome signatures for advanced prostate cancer (APC) starting androgen deprivation therapy (ADT) with or without abiraterone acetate and prednisolone (AAP): An ancillary study of the STAMPEDE AAP trial
Presenter: Marina Parry
Session: Proffered Paper session: GU tumours, prostate
Resources:
Abstract
Slides
Webcast
LBA62 - Comparison of abiraterone acetate and prednisolone (AAP) or combination enzalutamide (ENZ) + AAP for metastatic hormone sensitive prostate cancer (mHSPC) starting androgen deprivation therapy (ADT): Overall survival (OS) results of 2 randomised phase III trials from the STAMPEDE protocol
Presenter: Gerhardt Attard
Session: Proffered Paper session: GU tumours, prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA62 and 1358MO
Presenter: Elena Castro Marcos
Session: Proffered Paper session: GU tumours, prostate
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session: GU tumours, prostate
Resources:
Slides
Webcast
1357O - Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Fred Saad
Session: Proffered Paper session: GU tumours, prostate
Resources:
Abstract
Slides
Webcast
LBA63 - PRESTO: A phase III, open-label study of androgen annihilation in patients (pts) with high-risk biochemically relapsed prostate cancer (AFT-19)
Presenter: Rahul Aggarwal
Session: Proffered Paper session: GU tumours, prostate
Resources:
Abstract
Slides
Webcast